Could a cancer pill stop debilitating nosebleeds? new trial hopes so.
NCT ID NCT03850964
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a low dose of pazopanib, a drug currently used for cancer, can reduce severe nosebleeds and improve anemia in people with hereditary hemorrhagic telangiectasia (HHT). About 70 participants will take either the drug or a placebo daily for 24 weeks. Researchers will measure nosebleed duration and blood counts to see if the drug helps control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pazopanib (a low-dose cancer drug repurposed for HHT)
What this could lead to
If it works, this could offer a new daily pill to control severe nosebleeds and anemia in people with HHT, reducing the need for transfusions.
What could go wrong
This is a mid-stage trial with only 70 participants, so results may not apply to everyone. Pazopanib has side effects like high blood pressure and liver issues, and the placebo comparison means the real benefit is still uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Augusta University
Augusta, Georgia, 30912, United States
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
John Hopkins University
Baltimore, Maryland, 21287, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
University of California - Los Angeles
Los Angeles, California, 90095, United States
-
University of Colorado
Denver, Colorado, 80045, United States
-
University of North Carolina
Chapel Hill, North Carolina, 27514, United States
-
University of Texas - Southwestern
Dallas, Texas, 75390, United States
-
University of Utah Medical Center
Salt Lake City, Utah, 84132, United States
-
Washington University
St Louis, Missouri, 63110, United States